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ABSTRACT
Objective Gastro- oesophageal reflux disease (GERD) 
has heterogeneous aetiology primarily attributable to 
its symptom- based definitions. GERD genome- wide 
association studies (GWASs) have shown strong genetic 
overlaps with established risk factors such as obesity and 
depression. We hypothesised that the shared genetic 
architecture between GERD and these risk factors can 
be leveraged to (1) identify new GERD and Barrett’s 
oesophagus (BE) risk loci and (2) explore potentially 
heterogeneous pathways leading to GERD and 
oesophageal complications.
Design We applied multitrait GWAS models combining 
GERD (78 707 cases; 288 734 controls) and genetically 
correlated traits including education attainment, 
depression and body mass index. We also used multitrait 
analysis to identify BE risk loci. Top hits were replicated 
in 23andMe (462 753 GERD cases, 24 099 BE cases, 
1 484 025 controls). We additionally dissected the GERD 
loci into obesity- driven and depression- driven subgroups. 
These subgroups were investigated to determine how 
they relate to tissue- specific gene expression and to risk 
of serious oesophageal disease (BE and/or oesophageal 
adenocarcinoma, EA).
Results We identified 88 loci associated with GERD, 
with 59 replicating in 23andMe after multiple testing 
corrections. Our BE analysis identified seven novel loci. 
Additionally we showed that only the obesity- driven 
GERD loci (but not the depression- driven loci) were 
associated with genes enriched in oesophageal tissues 
and successfully predicted BE/EA.
Conclusion Our multitrait model identified many novel 
risk loci for GERD and BE. We present strong evidence for a 
genetic underpinning of disease heterogeneity in GERD and 
show that GERD loci associated with depressive symptoms 
are not strong predictors of BE/EA relative to obesity- driven 
GERD loci.
INTRODUCTION
Gastro- oesophageal reflux disease (GERD) is 
a complex condition with different consensus 
statements using a variety of clinical, endoscopic 
and physiological criteria to define the disease.1–3 
Although in a narrow sense, GERD can be consid-
ered the result of pathological oesophageal acid 
exposure4, the heterogeneous definition of GERD 
may help explain the range of traits that have been 
Significance of this study
What is already known on this subject?
 ► Gastro- oesophageal reflux disease (GERD) 
is a common but heterogeneous disorder, 
which increases one’s risk of developing 
Barrett’s oesophagus (BE) and oesophageal 
adenocarcinoma (EA). Previous studies have 
identified 25 genetic loci, which confer risk 
for a broad GERD phenotype and have shown 
genetic overlaps with risk factors such as 
obesity and depression.
What are the new findings?
 ► By leveraging genetic data on BE, GERD and its 
risk factors in a multitrait model, we identified 
88 risk loci for GERD and seven novel loci for 
BE. Stratifying the GERD loci by association 
on body mass index and depression revealed 
differences in gene expression across tissue 
types. Only loci falling in an obesity- driven 
GERD subgroup predicted the risk of BE/EA.
How might it impact on clinical practice in the 
foreseeable future?
 ► This study markedly increases our knowledge 
of the specific genes conferring GERD and BE 
risk. One subset of the GERD genes acts along 
a depression- driven GERD axis (and typically 
does not lead to downstream alterations of BE/
EA risk), while another subset demarcates an 
obesity- driven GERD axis, whereby a person’s 
genetic risk of GERD is likely to translate to a 
subsequent increase in risk of BE and EA.
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associated with GERD risk including obesity and psychological 
traits.5 6 GERD has risen in prevalence in many western countries 
in recent years and it now accounts for a substantial proportion 
of direct healthcare costs for digestive diseases.7 GERD is the 
major risk factor for Barrett’s oesophagus (BE), a precancerous 
condition in which GERD- induced erosions of the distal oesoph-
ageal squamous epithelium are replaced by metaplastic columnar 
epithelium.8 Most oesophageal adenocarcinomas (EA), a lethal 
malignancy with poor survival, arise from underlying BE tissue.9
Recent studies have sought to better understand GERD and 
its downstream consequences (BE, EA) by identifying the genes 
influencing risk of GERD. For most complex conditions, the 
most successful study design has been the genome- wide asso-
ciation study (GWAS), with large sample size and a key feature 
in successful studies. Initial GWAS for GERD failed to identify 
any risk genes,10 11 but more recent approaches using a broad 
phenotype definition to maximise sample size identified 25 risk 
loci.12 The recent GWAS also revealed strong genetic relation-
ships between GERD and a variety of traits.12 For example, there 
was a strong genetic correlation between depression and GERD, 
likely reflecting the psychological component previously shown 
to be associated with GERD.13 Another genetically correlated 
trait was obesity, an expected result given being overweight is a 
major risk factor for GERD.14
In this study, we took advantage of the genetic overlap between 
GERD and other traits12 to improve our power for gene discovery 
on GERD and BE. Because some of the traits most strongly 
correlated to GERD have been subjected to GWAS on a very 
large scale, there is potential for a large increase in gene mapping 
power if a multitrait approach is taken. We, hence, employed a 
multitrait approach using GERD and BE, alongside three traits, 
which had large sample sizes and high correlation with GERD: 
obesity, depression and educational attainment (EDU). We then 
replicated the GERD and BE loci in a large replication cohort 
and conducted gene enrichment and transcriptome- wide associ-
ation analyses. Finally, using BE as a clinical endpoint indicative 
of pathological erosive chronic acid reflux (rather than forms 
of symptomatic reflux associated with psychological traits such 
as depression), we then assessed the relevance of subsets of the 
GERD loci to serious oesophageal disease.
METHODS
Detailed methods are provided in online supplemental materials.
Overview of methods
Leveraging the strong genetic correlation between GERD and 
related traits, we applied a multitrait GWAS model combining 
GWASs for body mass index (BMI), major depressive disorder 
(MDD), education attainment and GERD (and BE), to identify 
more susceptibility loci for GERD and BE (figure 1). The brief 
description for each input GWAS in the multitrait GWAS analysis 
and the equivalent effect sample size is shown in online supple-
mental table ST1. Candidate loci for GERD and BE achieving 
genome- wide significance (p<5e-8) were sent for replication 
in the independent 23andMe cohort (4 62 753 cases; 1 127 474 
controls). Findings from these GWAS analyses were followed up 
with transcriptome- wide association studies (TWAS) and tissue 
enrichment analyses. TWAS analysis allows us to infer if there is a 
relationship between predicted gene- expression levels and GERD/
BE risk. Tissue enrichment analyses allow us to assess whether the 
relevant GERD/BE- associated genes showed differential enrich-
ment across 44 human tissues including oesophageal- related 
tissues. We finally applied a simple heuristic to dissect aetiological 
heterogeneity in GERD by separating GERD risk loci into obesity- 
driven and depression- driven categories; we then assessed these 
categories for differences in predicted gene expression in various 
tissues and for their ability to predict BE/EA susceptibility.
RESULTS
Multitrait analysis reveals 88 risk loci for GERD and 17 for BE 
with strong evidence of replication
In our multitrait GWAS combining GERD with BMI, MDD 
and EDU, we identified 88 GERD risk loci, where one or 
Figure 1 Schematic diagram describing overall study approach of the multi- trait GWAS analysis for GERD and BE susceptibility. GWAS data 
obtained from published studies are shown in bold. BE,Barrett’s oesophagus; EA,esophageal adenocarcinoma; EDU, Education Attainment; 
GERD,gastro- oesophageal reflux disease; GWAS, genome- wide association study; MDD, major depressive disorder; MTAG,multitrait analysis of GWAS; 
PGC, Psychiatric Genomics Consortium; QSKIN, Queensland Sun and Health Study; SSGAC, Social Science Genetics Association Consortium; UKBB, 
UK Biobank. Traits within the blue/red boxes are traits selected for the multi- trait GWAS analysis for GERD (blue) and BE (red). The trait BE was not 
modelled in the MTAG model for GERD, to avoid sample overlap bias in the genetic prediction analysis for GERD into the BE/EA datasets. Asterisk (*) 
highlights genetic correlation estimates for each trait against GERD (shown by the blue arrows) obtained from previous An et al12 findings.
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more single nucleotide polymorphisms (SNPs) exceeded 
genome- wide significance (5×10–8). There was no evidence 
for inflation of the GWAS test statistic (LD- Score intercept 
<1, QQ- plot in online supplemental figure 1). The associ-
ation estimates for each of the 88 lead SNPs are presented 
in online supplemental table ST2. To benchmark the power 
improvement resulting from our multitrait approach, we 
compared the average χ2 test statistic for GERD from the 
multitrait GWAS (1.72) with that from the standard univar-
iate GWAS (1.44); the increase corresponds to an estimated 
increase in GERD effective sample size of 64% (estimated via 
ratio of genomic inflation: (1.72–1)/(1.44–1)).12
The GWAS Manhattan plot for the multitrait GERD GWAS 
along with the circular Manhattan plot showing the contribution 
of the BMI and depression associations to the multitrait GERD 
GWAS are shown in figures 2A and 3. The associations between 
independent genome- wide significant GERD loci in the multi-
trait GWAS model (multitrait analysis of GWAS (MTAG)) against 
BMI, EDU and MDD are tabulated in online supplemental table 
ST3. The linkage disequilibrium among SNPs in each of the 88 
GERD loci is displayed via locusZoom plots in online supple-
mental figure 2). The vast majority (78 of 88) of the GERD–
MTAG associations replicated at an uncorrected p<0.05 level 
in the independent GERD validation sample from the 23andMe 
cohort, with 59 significant at p<0.05 after Bonferroni correction 
(ie, p<8.4×10-4) for 88 tests (online supplemental table ST2). 
The effect sizes for GERD in the MTAG and 23andMe replica-
tion analyses were highly consistent (r2=0.85) (figure 4A).
Our MTAG GWAS analysis focusing on BE discovered 17 
BE susceptibility loci achieving genome- wide significance. Of 
these, 14 replicated at p<2.9×10-3 (0.05/17) in the indepen-
dent 23andMe BE case–control cohort (online supplemental 
table ST4; QQ- plot in online supplemental figure 1). Relative to 
Gharahkhani et al,[15], seven of the loci were novel (rs2861695, 
rs10080150, rs10039754, rs622217, rs11792928, rs739414 and 
rs7187365). The effect sizes for BE in the MTAG and 23andMe 
replication analyses were highly consistent (figure 4B). Regional 
locusZoom plots for these novel loci are in online supplemental 
figure 3.
To assess whether our MTAG results were robust against 
issues of phenotypic heterogeneity, due to the use of self- report 
and inference through medication data that are diagnostically 
less reliable, we repeated our multitrait GWAS analyses using 
only GERD defined through the International Classification of 
Disease, tenth version (ICD-10) code (for GERD MTAG) and 
pathologically confirmed BE diagnosis (for BE MTAG). Differ-
ences in GERD and BE definition made no meaningful differ-
ence to the results, with strong correlations (r2 >0.99) observed 
between the SNP effect sizes of the original and revised MTAG 
models for both the GERD and BE analyses (online supplemental 
Figure 2 Manhattan plot for the multi- trait meta- analysed GWAS of GERD and BE. (A) for GERD; (B) for BE. The red dotted line indicates the 
genome- wide significance threshold at p=5×10-8. Single nucleotide polymorphisms (SNPs) with p values <0.01 were not shown. Loci with GERD 
association exceeding this threshold are deemed as a genome- wide GERD loci and followed up with the replication analysis in 23andMe. Each of 
the genome- wide loci is denoted with a red dot followed by the name of the relevant gene mapped through location proximity and expression 
quantiative trait loci (eQTL) information. BE,Barrett’s oesophagus; GERD, gastro- oesophageal reflux disease; GWAS, genome- wide association study.
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figures 4 and 5). Moreover, results from the MTAG BE model 
excluding MDD and EDU were not meaningfully different from 
the BE+GERD+BMI+MDD+EDU model (online supple-
mental table ST5), suggesting that at least for these BE risk loci, 
the associated SNPs act on BE risk either via BMI or via path-
ways to GERD, which are not shown to be robustly related to 
traits such as MDD.
Transcriptome-wide association analyses reveal more than 
200 genes associated with GERD and 49 with BE
Our metaXcan TWAS for GERD identified 37 significant 
genes when using expression quatitative trait loci (eQTL) 
information specifically derived from oesophageal muscu-
laris tissue. Similarly, TWAS on gastro- oesophageal junction 
and oesophageal mucosa tissue identified 19 and 37 genes, 
respectively (online supplemental table ST6). As well as 
conducting TWAS on the three oesophageal tissues above, we 
also employed a TWAS approach using a much broader range 
of tissues types in multiXcan; this identified 212 significant 
genes after multiple testing corrections (see online supple-
mental table ST7).
A multiXcan TWAS for BE identified 49 significant genes 
using a weighted SNP- eQTL association across multiple 
tissues (online supplemental table ST8). For a TWAS focusing 
solely on each of the three oesophageal- related tissues, we 
identified fewer significant genes (<10 per tissue, online 
supplemental table ST9). Among the genes identified via 
TWAS, 31 genes were associated with both GERD and BE 
(online supplemental figure 6).
Tissue enrichment analysis shows enrichment of GERD-
associated genes in brain tissues, but limited findings for BE 
genes
A tissue enrichment analysis based on the GERD genes mapped 
via the integrative web- based platform FUMA (available at 
http:// fuma. ctglab. nl) for functional annotation revealed 
strong evidence for differential expression among brain 
tissues, but with no clear signal in oesophageal tissues (online 
supplemental figure 7). For BE- associated genes, moderate 
enrichment was seen in brain Cerebellar hemisphere, brain 
cerebellum, colon, bladder and oesophageal tissues (both in 
the gastro- oesophageal junction and the oesophagus muscu-
laris), although the p values became nonsignificant after 
correction for multiple comparisons.
PheWAS analysis on novel hits for BE shows pleiotropic 
associations with other complex traits
As expected given our study design, and consistent with 
previous findings, the majority of GERD loci showed 
Figure 3 The circular Manhattan plot for BMI, MDD and the multitrait 
(MTAG) GERD GWAS. The trait from the innermost circle belongs to the 
(GIANT+UKB) Yengo et al. BMI GWAS39, followed by the Howard et al. 
(excluding 23andMe) MDD GWAS40 and the result from our multi- trait 
GERD GWAS. The plot illustrates different patterns of colocalisation 
between GERD and MDD/BMI for some regions, contributing to the 
genetic heterogeneity within GERD. BMI,body mass index; GERD, gastro- 
oesophageal reflux disease; GWAS, genome- wide association study; 
MDD, major depressivedisorder;MTAG, multitrait analysis of GWAS.
Figure 4 Replication of GERD and BE association for the genome- 
wide significant loci from MTAG analysis on GERD and BE in the 
23andMe cohort. A refers to the findings for GERD; (B) for BE. Data 
points that are shaded in blue are those that have a Bonferroni 
corrected p value below 0.05/88 for GERD and 0.05/17 for BE. Both the 
x- and y- axes represent log(OR) for GERD/BE and points are plotted 
with error bars representing one SE. Most of our GERD and BE loci 
showed strong evidence of being replicated, although the estimated 
effect size for GERD/BE in the 23andMe cohort were on average smaller 
than those estimated in the MTAG analysis (slope ~0.5 for both traits). 
BE,Barrett’s oesophagus; GERD, gastro- oesophageal reflux disease; 
MTAG, multitrait analysis of genome- wide association studies, SNP, 
single nucleotide polymorphism.
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pleiotropic associations with a variety of anthropo-
metric traits, education level, behavioural traits (including 
smoking).12 Several GERD genes were also associated with 
sarcoidosis, sleep duration and proxies of physical activity 
(online supplemental figure 8). A brief summary of our 
look- up for GERD loci driven by obesity and depression is in 
online supplemental table ST10.
For BE, again our study design leverages multiple input traits 
and, hence, pleiotropic associations are expected. PheWAS plots 
for the seven novel BE loci against traits available in the Open-
Target platform are provided in online supplemental figure 9. 
The BE- associated SNP rs10080150 is associated with risk of 
ulcerative colitis16, and rs7187365 and rs10039754 are associ-
ated with diaphragmatic hernia. Numerous BE SNPs (rs622217, 
rs10080150, rs11792928) showed pleiotropic associations with 
cardiovascular traits.
Genetic heterogeneity among the obesity-driven/depression-
driven GERD subgroups showing differential patterns of 
enrichment on oesophageal tissues and genetic prediction 
onto BE/EA
Of the 88 genome- wide GERD loci, we categorised 27 as 
depression- driven, 46 as obesity- driven GERD loci and 15 as 
indeterminate/unclear based on their relative contribution to 
GERD in the multitrait model. We then sought to validate 
these categories using two separate approaches.
In our first approach, we compared the categories in a 
tissue enrichment- based analysis. The mapped genes for SNPs 
from each category using eQTL information and proximity 
are shown in online supplemental tables ST11 and ST12.17 
While the regulation of gene expression was shown to be 
predominantly observed in brain tissues for the complete set 
of 88 genome- wide significant genetic loci, there were clear 
differences in the trend of gene expression across tissue types 
in the stratified obesity and depression driven subgroups 
(figure 5). Results for the directional (upward and down-
ward separately) differential regulation for both subgroups 
are presented in online supplemental tables ST13 and ST14; 
directional regulation plots and gene expression heatmaps 
in online supplemental figures 10-13. Genes mapped in the 
depression GERD subgroup remain predominantly expressed 
in brain tissues. In contrast, for genes in the obesity GERD 
subgroup as well as there being expression in brain tissues, a 
clear signal can be seen in oesophageal tissues (online supple-
mental figure 10).
In our second approach, we compared the SNP effect sizes 
for GERD with those from an independent BE/EA GWAS. 
Based on the 88 GERD susceptibility loci from the MTAG 
analysis, each one unit (log(OR)) increase in risk of BE/EA was 
associated with a 0.6 (p=4.2×10-10) unit (log(OR)) increase 
in GERD susceptibility (figure 6; summary data for BE/EA 
for the 88 GERD SNPs available in online supplemental table 
ST15). However, the Cochran Q statistics for the derived 
overall estimate suggested substantial evidence for effect size 
heterogeneity among GERD SNPs (p heterogeneity <0.001), 
indicating the potential for multiple biological mechanisms in 
action (online supplemental table ST16). We, hence, followed 
up with an association analysis for BE/EA based on the two 
Figure 5 MAGMA gene- based tissue enrichment analysis for categorised functional and non- functional GERD gene sets on 53 human tissues. The 
dotted line represents the Bonferroni corrected significance threshold. While both the obesity- driven and neuropsychiatric- driven GERD genes were 
differentially expressed in brain tissues, only the regulation of gene expression in oesophageal tissues were detected from the obesity GERD gene 
set. Another observation is that the pattern of regulation is more pleiotropic across tissues for the obesity GERD set, consistent with the complex 
architecture of adiposity. The results for up- ward and down- ward regulation of gene expression can be viewed in online supplemental materials. 
GERD,gastro- oesophageal reflux disease
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GERD subgroups. For GERD SNPs shown to be driven by 
obesity, the magnitude of association with BE/EA was 0.75 
(p=3.9×10–10) per unit log(OR) increase in GERD. In 
contrast, for GERD SNPs driven by neuropsychiatric factors 
correlated with depression, the magnitude of association with 
BE/EA was only 0.22 (p>0.05). The estimated effect size on 
BE/EA between the groups was substantially different (p value 
for difference=0.02). The inferences drawn for BE and EA 
taken separately were similar to the combined BE/EA find-
ings (online supplemental figures 14 and 15). Importantly, 
adjusting for BMI did not completely attenuate the genetic 
relationship between obesity- driven GERD and BE/EA (online 
supplemental table ST17).
DISCUSSION
Leveraging the known genetic correlation between GERD 
diagnosis with depression, EDU and anthropometric traits, we 
identified 88 independent GERD loci, with more than two- 
thirds showing clear evidence of replication in the independent 
23andMe cohort. Applying a similar multitrait model, we also 
discovered seven additional risk loci for BE that have not been 
previously reported. To the best of our knowledge, this is also 
the first study to have presented clear evidence for the existence 
of genetic subgroups within the complex and heterogeneous 
GERD (genetic) architecture.
Obesity and depression are known GERD risk factors; here, 
we first show that they can be combined to identify more loci for 
a broadly defined GERD phenotype, where we greatly expanded 
the number of GERD risk loci over and above previous GWAS 
findings12 through a multitrait model. More than two- thirds of 
the MTAG GERD loci replicated in 23andMe suggest that despite 
heterogeneous phenotyping being used, our findings represent 
genuine reflux loci. These results are also in good accord with 
our previous work showing high genetic concordance between 
these self- reported and clinical phenotypes. Second, we show 
that among the genome- wide significant GERD loci, a subgroup 
acts predominantly via effects on obesity while another acts via 
effects on depression. This is broadly consistent with previous 
observations that endoscopic findings18 in many (38%) patients 
with typical GERD symptoms are normal; in such cases, 
psychological factors may drive symptom reporting.19–23 We 
further showed that genes involved in the obesity- driven GERD 
subgroup were differentially expressed in oesophageal and 
adipose tissues—which was not evident from previous analyses 
evaluating GERD as a single, homogeneous disease.12 15
It was previously shown that psychosomatic factors are linked 
with functional oesophageal disorders through the gut- brain 
axis, which may alter a person’s emotional status, perception 
of pain and influence the self- reporting of GERD symptoms 
and severity.24 25 Previous studies have shown that among the 
broad class of individuals affected by GERD, those with func-
tional oesophageal disorders typically have normal oesophageal 
acid exposure26, and this may lead to them having lower risk of 
downstream BE/EA compared with other patients with GERD. 
Despite many studies showing strong association between 
depression with GERD (notably, the nonerosive reflux disease 
subtype),27 studies evaluating psychosomatic factors and BE/EA 
susceptibility had been more limited,28 29 likely due to sample 
size constraints. While there have been no large- scale obser-
vational studies to date to clarify any link between depression 
and BE, the previously documented weak correlation30 between 
GERD symptom scores (which correlates strongly with presence 
of a functional oesophageal disorder) and severity of esopha-
gitis, would imply that psychosomatic factors are unlikely to 
drive progression towards BE. Here, our results are in keeping 
with this as they show that the depression- driven GERD loci, 
which may predispose a person towards a functional oesoph-
ageal disorder rather than a disorder with abnormal oesopha-
geal acid exposure, have no effect on BE/EA risk. In contrast, we 
show that GERD risk loci acting via the obesity- driven pathway 
do have an effect on BE/EA risk (figure 6).
PheWAS results reveal that these novel loci are enriched with 
anthropometric traits and cardiovascular- related risk factors 
(online supplemental figure 9), perhaps as a result of a pleio-
tropic effect on obesity and cardiovascular disease. Given our 
results showing very weak association between depression- driven 
GERD and BE/EA, we did not expect to see pleiotropy between 
the BE- associated SNPs and depression; while this was broadly 
true, one of the novel BE loci (rs2861695) showed moderate 
evidence of association with depression (p<6.7e-4).31 Moreover, 
dropping proxies of socioeconomic status (EDU) and depression 
(MDD) from the model did not change our GWAS findings for 
BE (online supplemental table ST5). While our analyses showed a 
potential shared pathway between the obesity- driven GERD loci 
and BE, due to limited power, very few loci achieved genome- 
wide significance (ie, p<5e-8) across both traits. However, most 
of the BE loci did show suggestive evidence (ie, p<1e-5) of an 
association with GERD (online supplemental table ST18).
Two of the novel MTAG GERD loci, rs9636202 (nearest gene 
PGPEP1) and rs7206608 (nearest gene CDH13), were previ-
ously shown to be associated with periodontitis.32 33 Apart from 
actual pH- monitoring, periodontitis is also reported as one of 
the risk factors that are more commonly observed among cases 
with erosive GERD.34 35 However, whether the potential role of 
Figure 6 Estimation of the genetic association between GERD 
and BE/EA, stratified by genetic GERD subtypes. Each of the slopes 
represents the estimated magnitude of association between per unit 
increase in log(OR) of GERD on log(OR) of BE/OA, for all GERD loci 
(line in blue), obesity- driven GERD loci (line and points in green), and 
neuropsychiatric- driven GERD loci (line and points in orange) using 
an inverse variance weighted regression model. Cochran Q statistics 
indicated strong heterogeneity in the overall all- GERD estimate 
(p<0.001). In the stratified analysis, it becomes apparent that the 
overall estimate was primarily driven by the much stronger effect sizes 
from the obesity- driven GERD loci subset. BE,Barrett’s oesophagus (or 
Barrett’s esophagus); EA, oesophageal adenocarcinoma (or esophageal 
adenocarcinoma); GERD, gastro- oesophageal reflux disease; MTAG, 
multitraitanalysis of GWAS; SNP, single nucleotide polymorphism.
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PGPEP1 and CDH13 on reflux esophagitis and poor oral health 
represents a common effect on (1) dietary behaviour or (2) 
changes in adiposity (resulting in genetic associations with BMI) 
remains unclear. Our gene- based PheWAS identified substan-
tial overlap of GERD- associated genes with those involved in 
sarcoidosis, consistent with previous findings estimating one- 
third of patients with sarcoidosis being diagnosed with GERD- 
related symptoms and irritable bowel syndrome.36 Although 
fine- mapping is required to unambiguously link SNPs to genes, 
genes associated with several of the loci identified here (CRTC1, 
CDK2, PDE4B, DPYD, PDE1C) are targeted by drugs that are 
currently on trial for oesophageal and digestive system cancers.12 
Despite the fact that we have not undertaken the substantial task 
of unambiguously fine- mapping each associated GERD SNP to 
the relevant gene(s), many of the genes we identify here may be 
promising drug targets for further research.
Our observation of a greater magnitude of association 
between obesity- driven GERD loci and BE/EA is not surprising, 
given prior evidence37 showing that genetically predicted obesity 
was associated with increased risk of BE and EA. To evaluate 
whether obesity is a complete mediator between GERD and BE, 
we examined the genetic effect of obesity- driven GERD on BE 
adjusting for BMI and observed only partial attenuation (IVW- 
log(OR) from 0.726 (p=2.23e-8) to 0.513 (p=0.001)) of the 
GERD effect on BE (online supplemental table ST17). This 
implies that the relationship between GERD and BE cannot be 
solely explained by a common direct effect of obesity. Formal 
Mendelian randomisation (MR) analyses have been attempted 
previously38; however, interpreting the results from such studies 
is difficult given we have shown that there are at least two path-
ways leading to GERD (one acting via obesity associated SNPs, 
another acting via depression SNPs).
This study has several limitations. First, a proportion of UKB 
GERD cases was determined through use of heartburn- related 
medication12; however, as noted in our previous study, the genetic 
correlation between GERD inferred through medication, self- 
report and clinical diagnosis was very high. Similarly, our validation 
cohort (23andMe) adopted a broad GERD definition and diag-
nosis of BE were self- reported as opposed to being histologically 
verified. Overall, our approach of using a large GWAS sample size 
with a broad phenotype was much more effective in identifying 
novel loci than previous smaller studies using more well- defined 
phenotypes.10 11 Our heuristic for making the GERD obesity versus 
depression- driven subgroup classifications is limited by the accu-
racy of GWAS data, focused on only 88 SNPs, and, for ease of 
implementation, we used the BMI and depression GWAS results to 
group SNPs. Furthermore, while the combined effect of the obesity- 
driven GERD genome- wide significant loci (assembled in a genetic 
risk score) was robustly associated with BE/EA risk, the predictions 
from this genetic risk score lack precision to reliably predict BE/
EA in clinical settings. Finally, some SNPs may have pleiotropic 
effects on both obesity and on psychiatric traits or could simply 
reflect other pleiotropic pathways not mediated by these factors 
(eg, mucosal tight junctions, inflammation and repair, oesopha-
geal and gastric motility). Modelling these risk factors which are 
independent of the obesity and depression axis in our multitrait 
model could conceivably increase power to detect additional loci 
for both GERD and BE. GWAS studies on these additional traits are 
currently limited in size but investigating this will be worthwhile in 
future work.
In conclusion, using a multitrait framework, we greatly 
expanded the number of genome- wide significant genetic loci 
for GERD and also increased the number of BE loci by seven. 
Here, we present strong evidence for a genetic underpinning of 
disease heterogeneity in GERD, where we showed that GERD 
loci associated with depressive symptoms are not strong predic-
tors of BE/EA relative to obesity- driven GERD loci.
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